Vivos Therapeutics (VVOS) IPO Ramps 70% in Volatile Trade

Today's IPO for Vivos Therapeutics Inc. (NASDAQ: VVOS) is surging 71% to $10.25 after pricing its initial public offering of 3,500,000 shares of its common stock at a public offering price of $6.00 per share. Shares were briefly halted on volatility.

Roth Capital Partners is acting as lead book-running manager and representative of the underwriters for the offering. Craig-Hallum Capital Group and National Securities Corporation, a wholly owned subsidiary of National Holdings Corporation (NHLD) are acting as co-managers of the offering.

Vivos Therapeutics Inc. is a medical technology company focused on the development and commercialization of a highly differentiated technology offering a clinically effective non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). We believe our products and technology represent a significant improvement in the treatment of mild-to-moderate OSA versus other treatments such as continuous positive airway pressure (or CPAP

You May Also Be Interested In

• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• Citigroup set to join top banks in Anthropic IPO - Bloomberg
• Suja Life refinances credit agreement, cuts borrowing spread